翔宇SUNHOVER品牌怎么样 申请店铺

我要投票 翔宇SUNHOVER在滋补食材药材行业中的票数:612 更新时间:2026-02-13
翔宇SUNHOVER是哪个国家的品牌?「翔宇SUNHOVER」是 翔宇药业股份有限公司 旗下著名品牌。该品牌发源于山东省临沂市,由创始人林董在1999年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力翔宇SUNHOVER品牌出海!将品牌入驻外推网,定制翔宇SUNHOVER品牌推广信息,可以显著提高翔宇SUNHOVER产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

翔宇SUNHOVER怎么样

翔宇药业股份有限公司,山东省著名商标,孕产妇儿童补血知名品牌,高新技术企业,大型现代化民营制药企业


翔宇药业股份有限公司是翔宇集团控股上市公司,下辖一家全资子公司(山东仁和堂药业有限公司)和一家控股公司(山东诺维尔斯医药科技有限公司两家子公司)。拥有中药健康园、仁和堂化药园两大生产基地。生产妇科、儿科、精神、补益、心脑血管等11类制剂及原料药138个品种300多个品规。具有自主知识产权、自主定价权、国家中药保护品种及进入国家医保、基药、新农合目录的药品200多个。

翔宇药业坚持“打造中国妇幼用药一线药企”的企业发展战略,目前已经与3000多个经销商、100000多家医疗药店终端展开合作,销售网络遍布全国,部分产品远销欧美,为越来越多的家庭提供专业、优质的产品和服务!

化药盐酸地芬尼多取得美国DMF注册,盐酸米安色林、乳酸氟罗沙星原料药为国内独家产品替代进口,产品销往日本、墨西哥、美国等多个国家和地区。

翔宇药业严格按照新版GMP的要求设计,实施高标准GMP生产体系和质量体系,执行高于国标的内控标准。近年来,先后投入3.5亿元升级改造生产系统、生态处理系统。新建多功能提取车间及综合固体制剂车间,引进自动化控制系统、国际先进的药品检测设备,确保产品质量的稳定和优良。


Xiangyu Pharmaceutical Co., Ltd., a famous trademark of Shandong Province, a well-known brand of maternal and child blood supplement, a high-tech enterprise, and a large modern private pharmaceutical enterprise, Xiangyu Pharmaceutical Co., Ltd. is a listed company controlled by Xiangyu Group, which has a wholly-owned subsidiary (Shandong Renhetang Pharmaceutical Co., Ltd.) and a holding company (Shandong novels Pharmaceutical Technology Co., Ltd.) Subsidiaries). There are two production bases of Chinese medicine health park and Renhetang pharmaceutical park. More than 300 specifications of 138 varieties of 11 kinds of preparations and APIs, including Gynecology, pediatrics, spirit, tonic, cardio cerebrovascular and so on, are produced. There are more than 200 drugs with independent intellectual property rights, independent pricing rights, national protected varieties of traditional Chinese medicine and entering the national medical insurance, basic medicine and new rural cooperative medical insurance catalogue. Xiangyu pharmaceutical adheres to the enterprise development strategy of "building a first-line pharmaceutical enterprise of Chinese maternal and child medicine". At present, it has cooperated with more than 3000 distributors and 100000 Medical Pharmacy terminals. Its sales network spreads all over the country, and some products are exported to Europe and America, providing more and more families with professional and high-quality products and services! Difenidol hydrochloride, a chemical drug, has been registered with DMF in the United States. The raw materials of mianserin hydrochloride and fleroxacin lactate are the exclusive products in China, which are sold to Japan, Mexico, the United States and other countries and regions. Xiangyu pharmaceutical has designed in strict accordance with the requirements of the new GMP, implemented a high standard GMP production system and quality system, and implemented internal control standards higher than the national standard. In recent years, 350 million yuan has been invested in upgrading production system and ecological treatment system. New multi-functional extraction workshop and comprehensive solid preparation workshop, introduction of automatic control system, international advanced drug testing equipment, to ensure the stability and excellence of product quality.

本文链接: https://brand.waitui.com/c76e2d7a6.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

热门中概股美股盘前多数下跌,理想汽车跌超1%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,京东、B站、腾讯音乐、理想汽车跌超1%,百度跌0.94%,蔚来跌0.79%,小鹏汽车跌0.77%,阿里巴巴跌0.74%,爱奇艺跌0.52%;网易涨近1%。

60分钟前

翔鹭钨业:如钨精矿价格剧烈变化而钨制品价格未能同步变动,将对公司经营业绩产生影响

36氪获悉,翔鹭钨业公告,公司生产所需的钨精矿基本通过外购获得,公司产品的销售价格根据钨精矿价格变动情况相应调整,从而降低了原材料价格波动对公司经营业绩的影响,但如果未来钨精矿价格发生剧烈变化而钨制品价格未能同步变动,将会对公司主要产品的毛利率水平及经营业绩产生影响。

60分钟前

中芯国际:存储器、BCD供不应求都在涨价

36氪获悉,中芯国际公告,在11月份业绩说明会上,有提到存储大周期对于产业和晶圆代工业的影响。在这样的市场环境下,公司凭借在BCD、模拟、存储、MCU、中高端显示驱动等细分领域中的技术储备与领先优势、客户的产品布局,在本轮行业发展周期中,仍能保持有利位置。公司将积极响应市场的紧急需求,推动2026年收入继续增长。价钱是一种供需的关系。中芯国际的存储器、BCD供不应求,都是在涨价的,友商部分成熟的产能不做了,市场上的供应量是在下降的。

60分钟前

沪电股份:拟投资33亿元新建高端印制电路板生产项目

36氪获悉,沪电股份公告,公司于2026年2月11日召开的第八届董事会第十四次会议审议通过《关于新建高端印制电路板生产项目的议案》,同意投资新建“高端印制电路板生产项目”,生产高层数、高频高速、高密度互连、高通流PCB,以满足高速运算服务器、下一代高速网络交换机等对高端印制电路板的中长期增量需求。本项目总投资约为33亿元人民币,建成后预计年新增产能14万平方米高端印制电路板的生产规模,预计年新增营业收入30.5亿元人民币。

60分钟前

引航生物递表港交所

36氪获悉,据港交所,苏州引航生物科技股份有限公司向港交所提交上市申请书,独家保荐人为华泰国际。

60分钟前

本页详细列出关于翔宇SUNHOVER的品牌信息,含品牌所属公司介绍,翔宇SUNHOVER所处行业的品牌地位及优势。
咨询